{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:53:56Z","timestamp":1792155236491,"version":"4.4.0"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.juro.2013.04.031","type":"journal-article","created":{"date-parts":[[2013,4,17]],"date-time":"2013-04-17T05:16:09Z","timestamp":1366175769000},"page":"1200-1204","source":"Crossref","is-referenced-by-count":140,"title":["SWOG S0353: Phase II Trial of Intravesical Gemcitabine in Patients with Nonmuscle Invasive Bladder Cancer and Recurrence after 2 Prior Courses of Intravesical Bacillus Calmette-Gu\u00e9rin"],"prefix":"10.1097","volume":"190","author":[{"given":"Eila C.","family":"Skinner","sequence":"first","affiliation":[{"name":"Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Goldman","sequence":"additional","affiliation":[{"name":"SWOG Statistical Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael A.","family":"Sakr","sequence":"additional","affiliation":[{"name":"Wayne State University, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Petrylak","sequence":"additional","affiliation":[{"name":"Yale University, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz-Josef","family":"Lenz","sequence":"additional","affiliation":[{"name":"Keck USC School of Medicine, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl T.","family":"Lee","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shandra S.","family":"Wilson","sequence":"additional","affiliation":[{"name":"University of Colorado, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Benson","sequence":"additional","affiliation":[{"name":"Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth P.","family":"Lerner","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy M.","family":"Tangen","sequence":"additional","affiliation":[{"name":"SWOG Statistical Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"Thompson","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center, San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2013.04.031_bib1","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","article-title":"Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update","volume":"178","author":"Hall","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.04.031_bib2","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.eururo.2011.03.017","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update","volume":"59","author":"Babjuk","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2013.04.031_bib3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomized studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstrom","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2013.04.031_bib4","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.eururo.2006.01.017","article-title":"Management of BCG failures in superficial bladder cancer: a review","volume":"49","author":"Witjes","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2013.04.031_bib5","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2003.09.028","article-title":"Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study","volume":"21","author":"Laufer","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2013.04.031_bib6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1464-410X.2003.04656.x","article-title":"Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with\u00a0pharmacodynamics evaluation","volume":"93","author":"DeBerardinis","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2013.04.031_bib7","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2002.02.066","article-title":"Phase\u00a0I\u00a0trial of intravesical gemcitabine in bacillus Calmette-Gu\u00e9rin-refractory transitional-cell carcinoma of the bladder","volume":"20","author":"Dalbagni","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2013.04.031_bib8","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","article-title":"Phase II trial of intravesical gemcitabine in bacille Calmette-Gu\u00e9rin-refractory transitional cell carcinoma of the bladder","volume":"24","author":"Dalbagni","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2013.04.031_bib9","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.eururo.2007.02.063","article-title":"Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and\u00a0short-term therapy with bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma","volume":"52","author":"Friedrich","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2013.04.031_bib10","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/sim.4780110703","article-title":"Planned versus attained design in phase II clinical trials","volume":"11","author":"Green","year":"1992","journal-title":"Stat Med"},{"key":"10.1016\/j.juro.2013.04.031_bib11","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.eururo.2004.05.001","article-title":"Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC)","volume":"46","author":"Gontero","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2013.04.031_bib12","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.urology.2005.03.084","article-title":"Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent stage Ta urothelial cell carcinoma of the bladder","volume":"66","author":"G\u00e5rdmark","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.juro.2013.04.031_bib13","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/sj.bjc.6604074","article-title":"Activity of\u00a0endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study","volume":"97","author":"Gunelli","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.juro.2013.04.031_bib14","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","article-title":"Gemcitabine versus bacille Calmette-Gu\u00e9rin after\u00a0initial bacille Calmette-Gu\u00e9rin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial","volume":"116","author":"Di Lorenzo","year":"2010","journal-title":"Cancer"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534713040779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534713040779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2013.04.031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T23:26:22Z","timestamp":1651188382000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2013.04.031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1016\/j.juro.2013.04.031"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2013.04.031","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}